secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001213900-25-075678
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue
--------------------------------------------------------------------------------

- Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.
- BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.
- Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.
- Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/0001213900-25-075678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea0252991-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer